Action HLUN BH. LUNDBECK A/S
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués H. Lundbeck A/S

Actions

HLUN B

DK0061804770

Produits pharmaceutiques

Marché Fermé - Nasdaq Copenhagen
Autres places de cotation
 17:20:00 22/04/2025 		Varia. 5j. Varia. 1 janv.
27,54 DKK -3,57% Graphique intraday de H. Lundbeck A/S -3,97% -33,35%
08/04 Barclays abaisse le prix cible de Lundbeck à 46 (48) DKK et réitère sa pondération égale - BN FW
04/04 Lundbeck présentera des données positives sur son pipeline à l'AAN FW

Communiqués

Recherche
Voir les résultats
H Lundbeck A/S : Articles of Association (HLU Articles of Association 2025)
09/04
 PU
Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting
04/04
 AQ
Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention
31/03
 AQ
H Lundbeck A/S : Presentation (AGM Presentation 2025 03 26)
26/03
 PU
Lundbeck held its Annual General Meeting on 26 March 2025 at the company's registered office
26/03
 AQ
Rxulti[®] (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older
13/03
 AQ
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
10/03
 AQ
H Lundbeck A/S : NOTICE OF ANNUAL GENERAL MEETING (NOTICE OF ANNUAL GENERAL MEETING)
25/02
 PU
H Lundbeck A/S : Registration Form (Registration Form)
25/02
 PU
H Lundbeck A/S : Proxy and postal vote form (Proxy and postal vote form)
25/02
 PU
H Lundbeck A/S : Appendix 1 Remuneration Policy (Appendix 1 Remuneration Policy)
25/02
 PU
To the shareholders of H. Lundbeck A/S
25/02
 AQ
H Lundbeck A/S : Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
21/02
 PU
Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA
12/02
 AQ
H Lundbeck A/S : Transcript (ID20242271 Transcript Get Visual Lundbeck 2025 02 05 1200 CET)
07/02
 PU
Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
05/02
 AQ
H Lundbeck A/S : Corporate Governance Report (Lundbeck Corporate Governance Report 2024)
05/02
 PU
H Lundbeck A/S : Remuneration Report (Lundbeck Remuneration Report 2024)
05/02
 PU
H Lundbeck A/S : Annual report (Lundbeck Annual Report 2024)
05/02
 PU
H Lundbeck A/S : Investor Presentation (Lundbeck InvestorDeck FY2024)
05/02
 PU
H Lundbeck A/S : Release (Corporate Release FY2024 Final)
05/02
 PU
Lundbeck Annual Report 2024
05/02
 AQ
Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER)
05/02
 AQ
Lundbeck announces changes to the Board of Directors
04/02
 AQ
Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies
30/01
 AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action HLUN B
  4. Actualités H. Lundbeck A/S
  5. Communiqués
Etats-Unis

Zonebourse is also available in this country: United States.

Switch edition
Rester sur l'édition actuelle